A place to learn about building a new type of biotech that aims to better serve patients.

Videos, white papers, resources & opinions

White Paper & Video · 2026 · PDF

Genetic Targets, Financial Creativity

BridgeBio’s model for sustainable drug development

Biotech drug development is a high-risk, capital-intensive endeavor, requiring a balance between scientiﬁc advancement and ﬁnancial creativity.

Opinion · 2025

Congress must renew a popular, bipartisan FDA program benefitting sick kids

Thousands of children’s lives have been saved by a cost-free government initiative that expired last December. Congress needs to renew this program quickly because too many babies are dying needlessly.

White Paper · 2025 · PDF

Unlocking the feasibility of rare disease drug development

Millions of people are affected by rare diseases worldwide, yet fewer than 10% have approved treatments. This is largely because the high cost of drug development makes developing medicines infeasible for diseases with small patient populations.

Opinion · 2026

What makes a drug launch successful?

Having been fortunate to bring multiple medicines to market across several therapeutic areas, I have realized that the success of a launch is rarely attributed to one factor.

Podcast · May 2026

Neil Kumar on the Off-Target Effects podcast

Neil reflects on what it takes to serve patients well, build enduring capabilities, and create a sustainable biotech business in areas where others have historically been less focused.

Opinion & Video · May 2026

Scaling Innovation for Rare Diseases

Our CEO, Neil Kumar joined a panel moderated by CNBC Cure's Becky Quick to discuss how rewriting the rules will facilitate more rapid, cost-efficient, and scalable progress for the global rare disease community.